Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

• Published in: Clinical cancer research Vol. 30; no. 10; pp. 2160 - 2169
• Main Authors: Martín, Miguel, Yoder, Rachel, Salgado, Roberto, Del Monte-Millán, María, Álvarez, Enrique L, Echavarría, Isabel, Staley, Joshua M, O'Dea, Anne P, Nye, Lauren E, Stecklein, Shane R, Bueno, Coralia, Jerez, Yolanda, Cebollero, María, Bueno, Oscar, García Saenz, José Ángel, Moreno, Fernando, Bohn, Uriel, Gómez, Henry, Massarrah, Tatiana, Khan, Qamar J, Godwin, Andrew K, López-Tarruella, Sara, Sharma, Priyanka
• Format: Journal Article
• Language: English
• Published: United States 15.05.2024
• Subjects: Adult; Aged; Anthracyclines - administration & dosage; Anthracyclines - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - administration & dosage; Docetaxel - administration & dosage; Docetaxel - therapeutic use; Female; Humans; Lymphocytes, Tumor-Infiltrating - immunology; Middle Aged; Neoadjuvant Therapy - methods; Neoplasm Staging; Prognosis; Treatment Outcome; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - mortality; Triple Negative Breast Neoplasms - pathology

Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact of sTILs on refining outcomes beyond prognostic information provided by...